AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination with Chemotherapy in Patients with Relapsed/Refractory Leukemias Harboring a KMT2A/MLL Gene Rearrangement or Nucleophosmin 1 Mutation (mNPM1)

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Type of Study

Treatment

Locations

Childrens Hospital Colorado

Principal Investigator
Photograph of Kelly Faulk,  MD

Kelly Faulk, MD

Study ID

Protocol Number: 21-4798

More information available at ClinicalTrials.gov: NCT05326516

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers